- Home
- Publications
- Publication Search
- Publication Details
Title
The psychiatric side-effects of rimonabant
Authors
Keywords
-
Journal
REVISTA BRASILEIRA DE PSIQUIATRIA
Volume 31, Issue 2, Pages 145-153
Publisher
FapUNIFESP (SciELO)
Online
2009-07-02
DOI
10.1590/s1516-44462009000200012
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- [Commentary] TRIAL COMES TOO LATE AS PSYCHIATRIC SIDE EFFECTS END HOPE FOR RIMONABANT
- (2009) ADDICTION
- A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain
- (2009) Nancy A. Rigotti et al. ADDICTION
- The endocannabinoid system: emotion, learning and addiction
- (2008) Fabrício A. Moreira et al. ADDICTION BIOLOGY
- Effect of Rimonabant on the High-Triglyceride/ Low–HDL-Cholesterol Dyslipidemia, Intraabdominal Adiposity, and Liver Fat
- (2008) Jean-Pierre Després et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- The Acyclic CB1R Inverse Agonist Taranabant Mediates Weight Loss by Increasing Energy Expenditure and Decreasing Caloric Intake
- (2008) Carol Addy et al. Cell Metabolism
- SERENADE: The Study Evaluating Rimonabant Efficacy in Drug-Naive Diabetic Patients: Effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes
- (2008) J. Rosenstock et al. DIABETES CARE
- Efficacy and Safety of Rimonabant for Improvement of Multiple Cardiometabolic Risk Factors in Overweight/Obese Patients: Pooled 1-year data from the Rimonabant in Obesity (RIO) program
- (2008) L. Van Gaal et al. DIABETES CARE
- Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study †
- (2008) Luc F. Van Gaal et al. EUROPEAN HEART JOURNAL
- The cannabinoid CB1receptor and the endocannabinoid anandamide: possible antidepressant targets
- (2008) Francis Rodriguez Bambico et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Effect of Rimonabant on Progression of Atherosclerosis in Patients With Abdominal Obesity and Coronary Artery Disease
- (2008) Steven E. Nissen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Taranabant, a Novel Selective Cannabinoid-1 Receptor Inverse Agonist, for the Treatment of Obesity: Results From a Double-Blind, Placebo-Controlled, Single Oral Dose Study in Health
- (2008) Carol Addy et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Multiple-Dose Pharmacokinetics, Pharmacodynamics, and Safety of Taranabant, a Novel Selective Cannabinoid-1 Receptor Inverse Agonist, in Healthy Male Volunteers
- (2008) Carol Addy et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action
- (2008) Antonio Waldo Zuardi REVISTA BRASILEIRA DE PSIQUIATRIA
- Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists?
- (2008) Vincenzo Di Marzo Nature clinical practice. Cardiovascular medicine
- Antiaversive Effects of Cannabinoids: Is the Periaqueductal Gray Involved?
- (2008) F. A. Moreira et al. NEURAL PLASTICITY
- Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors
- (2007) Fabricio A. Moreira et al. NEUROPHARMACOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More